Playlist
Ashgabat Relocates 'Wokzal' Bus Terminal for Municipal and Intercity Routes
10 Jun. 13:46The Ashgabat Passenger Automobile Enterprise has officially announced a structural change in the city's transit network, relocating the terminal location of the "Wokzal" (Railway Station) bus stop. Serving high-capacity municipal buses under the "Yutong" brand, the newly established terminal is situated on the south-eastern side of the former site and has been operational since June 8, 2026.
The modernized transit point now handles the regular departures of municipal bus routes No. 20, No. 33, and No. 37. Upgraded infrastructure has been integrated at this location to ensure standard comfort and structured waiting conditions for daily commuters.
In addition to securing local municipal transport lines, the relocated hub serves as the primary departure platform for long-distance intercity bus services. Passengers can access long-distance routes traveling directly from this platform toward Awaza, Archman, Mollagara, Turkmenbashy, and Hazar.
This administrative adjustments aims to streamline passenger transportation within Turkmenistan's capital, enhance public safety parameters around the main railway district, and deliver an integrated environment for regional travel.
Also read
Simple Vitamin Shows Surprising Results in Pre-Cancerous Blood Conditions, Study Finds
Today in 02:02Daily high-dose supplementation of vitamin C can significantly reduce mortality risks and help prevent severe medical complications in patients with pre-cancerous blood conditions. Researchers from the Van Andel Institute in the United States and Copenhagen University Hospital in Denmark reached this conclusion following a comprehensive three-year follow-up study. The international "EVITA" trial involved volunteers who were administered 1,000 mg of vitamin C daily over the course of a year, while a control group received a placebo.
Although initial hypotheses suggested vitamin C might directly inhibit abnormal cell proliferation, researchers found its primary benefit lay in strengthening the body, reducing systemic inflammation, and lowering rates of anemia, pneumonia, and internal bleeding. Over the three-year observation period, the vitamin C group exhibited a significantly higher survival rate compared to the placebo group. While experts emphasize that these findings remain preliminary and require larger clinical trials before reshaping formal medical treatment protocols, vitamin C continues to show promising potential in supportive patient care.
Blitz